title: Insular infarct size but not levosimendan influenced myocardial injury triggered by cerebral ischemia in rats.
abstract: Cerebral injuries can trigger stress-related cardiomyopathy. The extent of cerebral injury and the involvement of the insular cortex influence the incidence and extent of myocardial injury (MI), and drugs with proven neuroprotective and cardioprotective properties such as levosimendan might be beneficial. This hypothesis was addressed in a rat model of transient middle cerebral artery occlusion. Transient brain ischemia was induced for 60 min by intraluminal occlusion of the middle cerebral artery in 40 male Wistar rats. Treatment with levosimendan (24 µg/kg) was started briefly before reperfusion. Hemodynamic parameters were recorded and cerebral and MI quantified after 24 h. Levosimendan treatment significantly reduced cerebral infarct size in the cortex, but not in the striatal and insular regions. However, its effects on survival (28 vs. 45%), incidence of MI (8 vs. 33%) as indicated by a troponin I (sTnI) threshold of 4.8 µg/L and large insular infarcts of ≥10 mm(3) (23 vs. 50%) failed to reach statistical significance. Blood pressure demonstrated significant differences related to insular infarct size during reperfusion. Levosimendan demonstrated no relevant effects on markers of MI (sTnI = 1.5 ± 2.8 vs. 5.3 ± 7.2 µg/L, P = 0.121). Insular infarct size could be identified as the only predictor of MI (odds ratio = 1.86, P = 0.037). In conclusion, the current investigation confirmed insular infarct size as a predictor of MI and source of hemodynamic compromise, but failed to demonstrate an effect of levosimendan on MI trigged by brain ischemia. A hardly protectable insular region might explain this.
authors.affiliation: Department of Anesthesiology, University Hospital Aachen, Pauwelsstrasse 30, 52074, Aachen, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Bleilevens
authors.forename: A B
authors.initials: AB
authors.lastname: Roehl
authors.forename: N
authors.initials: N
authors.lastname: Zoremba
authors.forename: R
authors.initials: R
authors.lastname: Tolba
authors.forename: R
authors.initials: R
authors.lastname: Rossaint
authors.forename: M
authors.initials: M
authors.lastname: Hein
mesh_terms: D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001921:Brain / Q000187:drug effects* / Q000473:pathology; D002545:Brain Ischemia / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D009202:Cardiomyopathies / Q000209:etiology / Q000473:pathology*; D006439:Hemodynamics / Q000187:drug effects; D006835:Hydrazones / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D011724:Pyridazines / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D000077464:Simendan
chemical_list: D006835:Hydrazones; D018696:Neuroprotective Agents; D011724:Pyridazines; D000077464:Simendan